{'fraction_non_alphanumeric': 0.02878684030157642, 'fraction_numerical': 0.01644962302947224, 'mean_word_length': 5.517857142857143, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation of Therapeutic Efficacy and Health Related Quality of Life of Anthracyclines Regimen and Taxanes with Anthracyclines Regimen in Node Positive Breast Cancer

Background: Chemotherapy with anthracyclines/taxanes is considered as an effective treatment option for breast cancer. Adjuvant chemotherapeutic options with anthracyclines or taxanes have improved disease free survival and overall survival rates in early breast cancer. The study is aimed to compare the therapeutic efficacy of anthracyclines containing regimen and sequential administration of taxanes with anthracyclines regimen for NODE positive breast cancer patients and to assess the Health-Related Quality of Life (HRQOL) of treated patients. Methods: This prospective open label study involved 14 patients who were treated with 6 cycles of 5-Fluorouracil (500mg/m2 ), Doxorubicin (50mg/m2 ), Cyclophosphamide (500mg/m2 ) [FAC] and 10 patients with 6 cycles of FAC plus 4 cycles of Paclitaxel (225mg/m2 ) [PAC]. Paired sample T test was used to assess the disease-free survival and reoccurrence rate. Time to progression was assessed by Kaplan Meir analysis and independent sample T test was used for assessing all the HRQOL parameters. Results: The disease-free survival was evaluated between the baseline and after 2 months of the chemotherapy which showed significant difference (p Key words: Anthracyclines, Adjuvant therapy, Breast cancer, Disease free survival, HRQOL, Taxanes.